Clinical ConvergenceĀ®: Patient and Provider Perspectives in IBD 2018

Gastroenterology
Curriculum:
Clinical ConvergenceĀ®: Patient and Provider Perspectives in IBD 2018
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
14-Dec-17
Expiration Date:
14-Dec-18

Primary Audience:

Gastroenterologists, gastroenterology nurse practitioners (NPs), and PAs

Relevant Terms:

Inflammatory bowel diseases (IBD), Crohn's disease, ulcerative colitis

Millie D. Long, MD, MPH

Millie D. Long, MD, MPH 
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Director, Gastroenterology and Hepatology Fellowship Program
University of North Carolina School of Medicine
Chapel Hill, NC

Millie D. Long, MD, MPH, earned her doctor of medicine degree at the University of Virginia, where she was a Bowman Scholar. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at the University of North Carolina at Chapel Hill. While at the University of North Carolina, she also completed a fellowship in preventive medicine, and a master’s of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology.
 
Dr Long is the director of the Gastroenterology and Hepatology Fellowship Program. She is also currently an associate professor of medicine in the division of gastroenterology and hepatology at the University of North Carolina. Her clinical practice is based at the University of North Carolina Inflammatory Bowel Diseases Center.
 
Dr Long’s interests include research on prevention of complications of inflammatory bowel disease and women’s health. She is an investigator for the Crohn’s & Colitis Foundation IBD Partners cohort, a prospective cohort focused on patient reported outcomes that includes over 15,000 patients living with inflammatory bowel disease. Dr Long has contributed numerous peer-reviewed publications, book chapters, and review articles to the medical literature. She serves as an invited reviewer for journals such as Inflammatory Bowel Diseases, Gastroenterology, and the American Journal of Gastroenterology. She is associate editor for the IBD section of the American Journal of Gastroenterology.
 
Dr Long is a member of the American College of Gastroenterology, where she serves on the Research Committee, and a member of the American Gastroenterological Association, where she serves on the maintenance of certification committee. She is also a member of the Crohn’s & Colitis Foundation, where she chairs the Professional Education Committee.

Meenakshi Bewtra, MD, MPH, PhD

Meenakshi Bewtra, MD, MPH, PhD
Assistant Professor of Medicine, Division of Gastroenterology
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania School of Medicine
Philadelphia, PA

Meenakshi Bewtra, MD, MPH, PhD, graduated from Yale University and received her medical degree from the University of Pennsylvania. She completed training in internal medicine and a fellowship in gastroenterology with specific training and expertise in inflammatory bowel disease (IBD). During her residency, Dr Bewtra also completed a Master’s in Public Health at the Harvard School of Public Health with a specific focus on epidemiology and biostatistics. She completed her PhD at the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennsylvania, with a focus on the use of discrete choice experiments in IBD research.
 
Dr Bewtra is an assistant professor of medicine in the division of gastroenterology and a senior scholar at the CCEB at the Perelman School of Medicine at the University of Pennsylvania. Dr Bewtra has been conducting clinical research for over a decade in IBD with a focus on the natural history of inflammatory bowel disease; outcomes of disease and medication safety using observational data and statistical modeling; measures of risk and risk tolerance for therapies using discrete choice experiment; and clinical trials for educational interventions and novel therapies.
 
Dr Bewtra is also the primary investigator (PI) of the IBD-Immunology Initiative (I3), a prospective clinical and tissue biobank actively enrolling all inflammatory bowel disease patients seen at the University of Pennsylvania. The I3 has collaborators within the University of Pennsylvania, nationally and internationally in both academia and industry, and is participating in several studies examining the basic mechanisms of IBD and predictors of response to therapies with the goal of improving personalized medicine in inflammatory bowel disease.
 
Dr Bewtra’s work has been funded by the National Institutes of Health (NIH), the Crohn’s & Colitis Foundation, American Gastroenterological Association (AGA), Patient-Centered Outcomes Research Institute (PCORI), pharmaceutical industries, and private philanthropy. She is a member of the Crohn’s & Colitis Foundation, the American Gastroenterological Association, and the American College of Gastroenterology

Derek R. Patel, MD

Derek R. Patel, MD
Clinical Professor of Medicine
Associate Clinical Services Chief
Division of Gastroenterology
University of California, San Diego
San Diego, CA

Derek R. Patel, MD, earned his doctor of medicine degree at the University of California Davis School of Medicine. He completed a residency at the University of California, San Francisco, in the department of medicine, and completed a gastroenterology fellowship at University of California, San Francisco, in the division of gastroenteroloy. Dr Patel received additional training at the Cedars-Sinai Medical Center’s Inflammatory Bowel Disease Center in Los Angeles, California. He is board certified in internal medicine and gastroenterology.
 
Dr Patel is the associate clinical services chief of Hillcrest Gastroenterology. He also participates in teaching activities through the University of California San Diego School of Medicine.
 
Dr Patel’s interests include research on inflammatory bowel disease, emergency department evaluation and management of patients with IBD, and other gastroenterological issues. Due to his research and expertise, Dr Patel has accepted invitations to participate in numerous presentations. Dr Patel has contributed numerous abstracts and publications to medical literature, and has published work in journals such as Clinical Gastroenterology Hepatology and Clinical Nephrology.
 
Dr Patel is a member of the American Gastroenterological Association, World Gastroenterology Organization, and the Crohn’s & Colitis Foundation, among others. He also serves as an ad hoc reviewer for Digestive Diseases and Sciences and Inflammatory Bowel Diseases.
1. Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
2. Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity 
3. Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
4. Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making 

CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation Statement
The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE DECLARATION
According to the disclosure policy of the University of Cincinnati, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
 
In accordance with the ACCME Standards for Commercial Support, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (eg, paid speaker, employee, paid consultant on a board, and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:
 
Millie D. Long, MD, MPH, discloses the following relationships with commercial interests: AbbVie Inc., Pfizer Inc., Takeda Pharmaceuticals USA, Inc., and TARGET PharmaSolutions (Consultant); Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. and UCB (Speaker).
 
Meenakshi Bewtra, MD, MPH, PhD, discloses the following relationships with commercial interests: Janssen Pharmaceuticals, Inc. (Consultant); GlaxoSmithKline and Takeda Pharmaceuticals USA, Inc. (Research Support); and AbbVie Inc. (Speaker).
 
Derek R. Patel, MD, discloses the following relationships with commercial interests: AbbVie Inc. (Consultant) and AbbVie Inc. (Speaker).
 
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
 
Crohn’s & Colitis Foundation
Sudha Sarode, MSPH, has no relevant relationships to disclose.
 
RMEI Medical Education, LLC
Sherri Kramer, MD, has no relevant relationships to disclose.
Tania Dickson has no relevant relationships to disclose.
Jessica Hatch has no relevant relationships to disclose.
 
University of Cincinnati
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, CME Director, has no relevant relationships to disclose.
Rick E. Ricer, MD, Professor Emeritus, has no relevant relationships to disclose.
Deborah Cole, BS, has no relevant relationships to disclose.
 
OFF-LABEL DISCLOSURE STATEMENT
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
 
LEARNER ASSURANCE STATEMENT
The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
 
DISCLAIMER STATEMENT
The opinions expressed during the enduring material activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
  
Estimated time to complete: 1.0 hour 
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by independent educational grants from AbbVie Inc., Celgene Corporation, Salix Pharmaceuticals, and Takeda Pharmaceuticals USA, Inc.

HOW TO RECEIVE CREDIT
By completing the curriculum challenge (at the beginning and again at the end of the activity), the pre test, reviewing the course content, and successfully completing the post test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1.0 AMA PRA Category 1 Credit™. A statement of credit will be available to print from your user history page.
 
Users must:
  1. Read the learning objectives and faculty disclosures.
  2. Participate in the activity.
  3. Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post test and evaluation will receive CME credit. You must score 75% or higher on the post test to receive credit for this activity. All other participants who successfully complete the post test and evaluation will receive a certificate of participation.
 
Contact Information:
 
Accreditation Support
Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or by calling 513-558-7277.
 
Technical Support:
For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.